S. Qin

Cost-effectiveness analysis of five drugs for treating postmenopausal women in the United States with osteoporosis and a very high fracture risk

X. Wan, C. Luo, Shuxia Qin, 2022, Journal of Endocrinological Investigation.

Cost-Effectiveness Analysis of Cemiplimab Versus Chemotherapy as First-Line Treatment in Advanced NSCLC with PD-L1 Expression Levels of at Least 50%

Chongqing Tan, Liubao Peng, X. Wan, 2021, Advances in Therapy.

Sequences of biological treatments for patients with moderate-to-severe rheumatoid arthritis in the era of treat-to-target in China: a cost-effectiveness analysis

Chongqing Tan, Liubao Peng, Lidan Yi, 2021, Clinical Rheumatology.

Cost-Effectiveness of Atezolizumab Plus Chemotherapy as First-Line Therapy for Metastatic Urothelial Cancer

Chongqing Tan, Lidan Yi, X. Wan, 2021, Advances in Therapy.

Trametinib for patients with recurrent low-grade serous ovarian cancer: A cost-effectiveness analysis.

Meiyu Wu, Zhiyao Tang, X. Wan, 2022, Gynecologic oncology.

Cost-Effectiveness of Nivolumab Plus Ipilimumab Combined with Two Cycles of Chemotherapy as First-Line Treatment in Advanced Non-Small Cell Lung Cancer

Chongqing Tan, Qiao Liu, X. Luo, 2021, Advances in Therapy.

Efficacy of Cognitive Behavioral Therapy for Heart Failure A Meta-Analysis of Randomized Controlled Studies

Wei Huang, Junjie Fang, Shuxia Qin, 2019 .